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Abstract
Background: The prognostic importance of anemia for cardiovascular (CV) events and mortality has been extensively
investigated. However, little is known about the impact of transferrin saturation (TSAT), a marker reflecting the availability of
iron for erythropoiesis, on clinical outcome in dialysis patients.
Methods: A total of 879 anemic incident dialysis patients were recruited from the Clinical Research Center for End-Stage
Renal Disease in Korea and were divided into 3 groups according to baseline TSAT of #20%, 20–40%, and .40%.
Results: There were no differences in hemoglobin levels and the proportion of patients on erythropoiesis-stimulating
agents or iron supplements among the 3 groups. During a mean follow-up duration of 19.3 months, 51 (5.8%) patients died.
CV composite (11.71 vs. 5.55 events/100 patient-years, P = 0.001) and all-cause mortality rates (5.38 vs. 2.31 events/100
patient-years, P = 0.016) were significantly higher in patients with TSAT #20% compared to those with TSAT 20–40%
(reference group). Cox regression analysis revealed that patients with TSAT#20% had 1.62- and 2.19-fold higher risks for CV
composite outcome (P = 0.046) and all-cause mortality (P = 0.030). Moreover, TSAT #20% was significantly associated with
left ventricular hypertrophy [odds ratio (OR) = 1.46], high-sensitivity C-reactive protein $3 mg/dL (OR= 2.09), N-terminal
pro B-type natriuretic peptide $10000 pg/mL (OR = 2.04), and troponin-T$0.1 ng/mL (OR = 2.02), on logistic regression
analysis.
Conclusions: Low TSAT was a significant independent risk factor for adverse clinical outcome in incident dialysis patients
with anemia, which may be partly attributed to cardiac dysfunction and inflammation.
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Introduction
Anemia is prevalent in patients with chronic kidney disease
(CKD), and develops during the early stages of the disease and
worsens as renal function declines [1,2]. It is well known that
anemia is closely linked with fatigue, exercise intolerance, and
poor quality of life. In addition, anemia has been demonstrated to
be an independent risk factor for left ventricular hypertrophy
(LVH), congestive heart failure (CHF), and cardiovascular (CV)
mortality [3–5]. In CKD patients, anemia is also associated with
the progression of renal dysfunction [6,7].
Anemia in CKD patients is attributed to inadequate production
of erythropoietin, iron and/or folate deficiency, secondary
hyperparathyroidism, chronic inflammation, and bone marrow
suppression due to uremic toxins [8]. Among these factors except
for erythropoietin deficiency, iron deficiency is the leading cause of
anemia in patients with CKD. Therefore clinicians must
determine patients’ iron levels not only at the start of erythropoi-
esis-stimulating agent (ESA) therapy but also monitor iron levels
during ESA treatment in this population [9,10]. To evaluate iron
status, serum iron concentrations, transferrin saturation (TSAT);
the ratio of serum iron to total iron-binding capacity (TIBC),
multiplied by 100, and serum ferritin levels are commonly used.
While serum iron concentrations and TSAT reflect the amount of
iron available for erythropoiesis, serum ferritin levels are the only
marker of total body iron stores. Ferritin levels also are greatly
influenced by nutritional and/or inflammatory status and do not
correlate well with bone marrow findings in patients with various
chronic diseases [11]. Considering these findings, TSAT ,20%
and serum ferritin concentrations ,100 ng/mL are regarded as
absolute iron deficiency, and TSAT ,20% and serum ferritin
levels .100 ng/mL as relative iron deficiency [9,11].
Iron is an essential nutrient. It plays critical roles in binding and
transporting oxygen, oxidative metabolism by serving as a
component of the mitochondrial respiratory chain proteins, and
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the synthesis of DNA and protein [12]. Therefore, iron deficiency
may result in numerous pathologies, especially in cells with high
energy demands, such as cardiomyocytes [13,14]. In addition to its
association with poor cognitive function, reduced exercise
performance, and decreased quality of life, previous studies have
found that absolute or relative iron deficiency, regardless of the
presence of anemia, is an independent predictor of adverse clinical
outcomes, including a progression of CHF and mortality, in
patients with CHF [15–18]. These findings suggest that lack of
circulating available iron has a direct deleterious effect on the
heart.
Since CV disease is the most common cause of morbidity and
mortality in patients with end-stage renal disease (ESRD), it
follows that iron deficiency may have a negative impact on the
clinical outcome of ESRD patients. However, to date, this effect
has never been evaluated in this population. In the present study,
therefore, we investigated whether low TSAT was a significant
predictor of CV mortality/composite outcome and all-cause
mortality in Korean incident dialysis patients from the Clinical
Research Center (CRC) for ESRD. The relationships of TSAT
with echocardiographic parameters and cardiac biomarkers were
also defined in these patients.
Patients and Methods
Ethics statement
This study was carried out in accordance with the Declaration
of Helsinki and study protocol was approved by the Institutional
Review Board of each participating hospital’s Clinical Trial
Center (CTC); Kyungpook National University Hospital CTC,
Youngnam University Medical Center CTC, Dong-A University
Medical Center CTC, Busan National University Hospital CTC,
Inje University Pusan Paik Hospital CTC, Ulsan University
Hospital CTC, Seoul National University Hospital CTC, Seoul
National University Bundang Hospital CTC, Seoul National
University Boramae Hospital CTC, Gachon University Gil
Medical Center CTC, Yonsei University Health System CTC,
National Health Insurance Corporation Ilsan Hospital CTC,
Ehwa Womens University Mokdong Hospital CTC, Kwandong
University College of Medicine Myongi Hospital CTC, Kangnam
Severance Hospital CTC, The Catholic University of Korea Seoul
St. Mary’s Hospital CTC, The Catholic University of Korea
Yeouido St. Mary’s Hospital CTC, The Catholic University of
Korea Bucheon St. Mary’s Hospital CTC, The Catholic
University of Korea St. Vincent’s Hospital CTC, The Catholic
University of Korea Uijeongbu St. Mary’s Hospital CTC, Chung-
Ang University Health System CTC, Chonnam National Univer-
sity Hospital CTC, Chungnam National University Hospital
CTC, Chungbuk National University Hospital CTC, Chonbuk
National University Hospital CTC, and Cheju Halla General
Hospital CTC. All patients provided their written informed
consent before entering the study.
Patients
Initial recruitment for this prospective observational multicenter
study included all ESRD patients who started dialysis between
August 1, 2008 and December 31, 2012 at 27 centers of the CRC
for ESRD in Korea. Among these patients, we excluded those who
were younger than 18 years old, had a history of kidney
transplantation prior to dialysis therapy, had an underlying active
malignancy or acute infection, or died within 3 months of the
initiation of dialysis. Patients who were not anemic; anemia was
defined as Hb ,13 g/dL in men and ,12 g/dL in women
according to World Health Organization (WHO) criteria [19],
had a recent bleeding episode, or had insufficient baseline data
were also excluded from the study. Ultimately, a total of 879
incident dialysis patients were included in the final analysis.
Data Collection
Demographic and clinical data were recorded at the time of
study entry, including age, gender, body mass index (BMI)
calculated as weight/height2, primary renal disease, comorbidities,
and medications. Coronary arterial disease (CAD) was defined as a
history of angioplasty, coronary artery bypass grafts, myocardial
infarction, or angina, while peripheral arterial disease (PAD) was
defined as a history of claudication, ischemic limb loss and/or
ulceration, or peripheral revascularization procedure. At the time
of study entry and every 3 months thereafter, laboratory data were
measured from fasting blood samples, which were drawn prior to
the start of hemodialysis (HD) on the day of a midweek session in
HD patients and at 2-hours after the first peritoneal dialysis (PD)
exchange with 1.5% dextrose dialysate in PD patients. The
estimated glomerular filtration rate (eGFR) was calculated using
the four-variable Modification of Diet in Renal Disease study
(MDRD) and Chronic Kidney Disease Epidemiology Collabora-
tion study (CKD-EPI) equations [20]. In addition, a 24-hour urine
collection was performed to determine residual urine volume, and
24-hour urinary protein, urea, and creatinine excretion. Nutri-
tional status was also evaluated by the subjective global assessment
(SGA) score [21]. The quality of life was assessed using a Korean
version of Kidney Disease Quality of Life Short Form (KDQOL-
SF, version 1.3) [22].
Echocardiography was performed on a non-dialysis day in HD
patients and in the morning with an empty abdomen in PD
patients, close to the time of discharge, based on the imaging
protocol recommended by the American Society of Echocardiog-
raphy. Left atrial dimension (LAD) was assessed at the end of the
ventricular systole at the level of the aortic valve, according to the
leading-edge-to-leading-edge convention. Left ventricular (LV)
mass was determined using the method described by Devereux
et al. [23], and the LV mass index (LVMI) was calculated by
dividing LV mass by body surface area. LV hypertrophy (LVH)
was defined as a LVMI .131 g/m2 for men and .100 g/m2 for
women [24]. LV systolic function was estimated by the LV
ejection fraction (LVEF) using a modified biplane Simpson’s
method from the apical two-chamber and four-chamber views.
Inter-ventricular septal thickness (IST), left ventricular posterior
wall thickness (LVPWT), and left ventricular dimensions
(LVEDD, LVESD) were also measured at the end of both the
diastolic and systolic phases. Multiple reproducibility, inter-reader
reliability, intra-reader reliability, and reader drift analyses were
performed at a core echocardiography laboratory (Kyungpook
National University, Daegu, Korea) on a random sample of 3% of
the entire cohort each year. The intra-class correlation coefficients
for the echocardiographic measures were 0.773 for LAD, 0.745 for
LVMI, and 0.842 for LVEF.
Outcome measures
For the current study, all mortality and hospitalization event
records were retrieved from the CRC for ESRD database and
carefully reviewed. The primary endpoints were CV mortality and
CV composite outcome (death and hospitalization), and the
secondary endpoint was all-cause mortality. CV event was
considered death or hospitalization from myocardial infarction/
ischemia, congestive heart failure, pulmonary edema, or cerebro-
vascular disorder.
The Impact of TSAT on Clinical Outcome
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Statistical analysis
Statistical analysis was performed using SPSS for Windows,
version 18.0 (SPSS Inc., Chicago, IL, USA). Data are expressed as
mean 6 standard deviation or median (interquartile range) for
continuous variables, and as a number (percentage) for categorical
variables. Normality of distribution was assessed by the Shapiro-
Wilk test. Patients were categorized into 3 groups according to
TSAT concentrations; #20%, 20–40%, and .40%. Patient
demographics, clinical characteristics, and laboratory findings
were compared among the three groups using ANOVA or
Kruskal-Wallis test for continuous variables and the chi-square test
for categorical variables. Cumulative survival curves for CV
mortality, CV composite outcome, and all-cause mortality were
created by the Kaplan-Meier method, and between-group survival
was compared by a log-rank test. The independent prognostic
power of TSAT for clinical outcomes was ascertained by
multivariate Cox proportional hazards regression analysis, which
included only the variables of a P-value ,0.10 on the univariate
analysis. Binary logistic regression analysis was conducted to
determine the independent predictive value of TSAT for
echocardiographic parameters (LVEF ,60%, LVH, LVEDD $
55 mm, LVESD$35 mm, and LAD$40 mm) and inflammatory
and cardiac biomarkers [high-sensitivity C-reactive protein (hs-
CRP) $3 mg/dL, N-terminal pro B-type natriuretic peptide (NT-
proBNP) $10000 pg/mL, and cardiac troponin-T (cTnT) $
0.1 ng/mL]. A P-value of less than 0.05 was considered
statistically significant.
Results
Baseline characteristics
The baseline demographics and clinical characteristics are
shown in Table 1. The mean age was 56.4614.5 years, and
59.6% of patients were male. The most common cause of ESRD
was diabetes (DM, 52.7%), followed by hypertension (16.5%). A
total of 645 patients (73.4%) were treated with HD and 234
patients (26.6%) with PD. The mean values of hemoglobin (Hb)
and TSAT were 8.661.4 g/dL and 28.4616.0%, respectively,
and the median levels of ferritin were 201.3 (103.5–363.4) ng/mL.
When patients were divided into three groups according to
baseline TSAT concentrations, age, sex, the proportion of patients
on HD, the presence of DM and CV diseases, and KDQOL-SF
scores were comparable among the three groups. There were also
no differences in the proportions of patients on renin-angiotensin
system (RAS) blockers, ESA, and supplementary iron. However,
beta-blockers were more frequently prescribed in the lowest TSAT
group compared to the other groups (P= 0.019) (Table 1). Even
though only one third of patients (n = 319, 36.3%) were on iron
therapy at the time of dialysis commencement, 166 patients with
TSAT #20% (58.9%) were newly treated with iron agents after
the initiation of dialysis. Therefore, 261 patients (92.6%) with
initial TSAT #20% were on iron therapy at 3-month.
Within the laboratory and echocardiographic findings, blood
urea nitrogen and creatinine levels were significantly lower in the
lowest TSAT group compared to the highest TSAT group (P,
0.001), whereas serum calcium, bicarbonate, and triglyceride
concentrations were significantly higher (P,0.05). There were also
significant gradual increases in serum iron and ferritin concentra-
tions and a significant gradual decrease in TIBC levels across the
TSAT groups (P,0.001). However, eGFR and Hb concentrations
were not significantly different among the three groups. Mean-
while, hs-CRP and NT-proBNP levels were significantly higher in
the lowest TSAT group compared to the other two groups (P,
0.001 and P= 0.011, respectively). Echocardiographic parameters
were comparable among the three groups (Table 2).
CV mortality, CV composite outcome, and all-cause
mortality according to TSAT concentrations
During a mean follow-up duration of 19.3611.8 months, 51
patients (5.8%) died. Among them, 29 patients (3.3%) died from
CV causes and 12 (1.4%) from infection.
Compared to the reference group (TSAT 20–40%), CV
composite and all-cause mortality rates were significantly higher
in patients with TSAT #20% (CV composite: 11.71 vs. 5.55
events per 100 patient-yr, P= 0.001; all-cause mortality: 5.38 vs.
2.31 events per 100 patient-yr, P = 0.016). In contrast, there was
no significant difference in CV mortality rates among the three
groups (Table 3). Kaplan-Meier analysis also showed that the CV
composite and all-cause mortality rates were significantly higher in
patients with TSAT #20% compared to the other two groups
(P= 0.009 and P= 0.046, respectively) (Figure 1). However, there
was no significant difference in the CV composite and all-cause
mortality rates between the reference and TSAT .40% groups.
Multivariate Cox-proportional hazard regression analysis re-
vealed that patients in the lowest TSAT group had 1.62- and 2.19-
fold higher risks for CV composite outcome and all-cause
mortality, respectively, even after adjusting for demographic
characteristics, laboratory findings, and echocardiographic pa-
rameters (P = 0.046 and P= 0.030, respectively) (Table 4).
In another analysis, we simply dichotomized patients into ‘low’
and ‘normal to high’ TSAT groups based on TSAT concentra-
tions of 20%, and compared the clinical outcomes between the two
groups. The ‘low’ TSAT group had significantly higher rates of
CV composite (11.71 vs. 6.15 events per 100 patient-yr, P,0.001)
and all-cause mortality (5.38 vs. 2.74 events per 100 patient-yr,
P= 0.008) than patients with TSAT .20%, and the hazard ratios
(HRs) were 1.53 and 2.04, respectively, on the multivariate Cox
regression analysis (Table S1 and S2, and Figure S1).
Relationships between TSAT and echocardiographic
parameters
In binary logistic regression analysis for echocardiographic
parameters, TSAT #20% was demonstrated to be significantly
associated with LVH [odds ratio (OR) = 1.46, P= 0.048]. The
ORs of TSAT #20% for LVEF ,60%, LVEDD $55 mm,
LVESD $35 mm, and LAD $40 mm were also increased, but
did not reach statistical significances (Table 5).
Based on these results, we performed an additional multivariate
linear regression analysis for LVMI. Along with diastolic blood
pressure, underlying CV disease, SGA score, smoking status,
serum Hb and albumin concentrations, and usage of RAS
blockers, calcium-based phosphate binders, and iron agents,
TSAT #20% was a significant independent determinant of
LVMI (R= 7.151, P= 0.044) (Table S3).
Relationships between TSAT and serum inflammatory
and cardiac biomarkers
Binary logistic regression analysis revealed that there were
significant independent associations of TSAT #20% with hs-CRP
$3 mg/dL (OR=2.09, P= 0.003), NT-proBNP $10,000 pg/mL
(OR =2.04, P= 0.011), and cTnT $0.1 ng/mL (OR =2.02,
P= 0.023) (Table 6).
In an additional multivariate linear regression analysis, TSAT
#20% was found to be a significant determinant of natural log
values (Ln) of hs-CRP levels (R= 0.304, P,0.001), but not of Ln
The Impact of TSAT on Clinical Outcome
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Table 1. Baseline demographic and clinical characteristics of the patients.
Variables Total TSAT #20% TSAT 20–40% TSAT .40% P
N 879 282 431 166
Age (years) 56.4614.5 57.1614.0 56.4614.2 55.3616.2 0.414
Sex (Male) 524 (59.6) 162 (57.4) 258(59.9) 104 (62.7) 0.550
BMI (kg/m2) 23.263.7 23.363.7 23.463.8 22.663.3 0.097
Systolic BP (mmHg) 142.4624.7 142.2624.7 142.7625.4 141.7622.9 0.898
Diastolic BP (mmHg) 77.6615.2 76.9615.0 77.8615.3 78.1615.1 0.666
Heart rate (beat per minute) 76.7613.6 76.9613.0 76.8613.1 76.2615.7 0.845
Dialysis modality (HD) 645 (73.4) 212 (75.2) 310 (71.9) 123 (74.1) 0.614
Follow-up duration (months) 19.3611.8 19.8611.6 19.3611.7 18.6612.3 0.562
Smoking status 0.878
Current smoker 103 (11.7) 31 (11.0) 51 (11.8) 21 (12.7)
Ex-smoker 291 (33.1) 92 (32.6) 143 (33.2) 56 (33.7)
Non-smoker 467 (53.1) 155 (55.0) 225 (52.2) 87 (52.4)
Unknown 18 (2.0) 4 (1.4) 12 (2.8) 2 (1.2)
Primary cause of end-stage renal disease 0.151
Diabetes 463 (52.7) 162 (57.4) 228 (52.9) 73 (44.0)
HTN/Large vessel disease 145 (16.5) 43 (15.2) 75 (17.4) 27 (16.3)
Glomerulonephritis 147 (16.7) 38 (13.5) 67 (15.5) 42 (25.3)
Interstitial nephritis 9 (1.0) 3 (1.1) 5 (1.2) 1 (0.6)
Hereditary/Congenital disease 15 (1.7) 7 (2.5) 6 (1.4) 2 (1.2)
Others 43 (4.9) 11 (3.9) 24 (5.6) 8 (4.8)
Unknown 57 (6.5) 18 (6.4) 26 (6.0) 13 (7.8)
Comorbid disease
Chronic lung disease 72 (8.2) 20 (7.1) 32 (7.4) 20 (12.0) 0.130
CAD 127 (14.4) 48 (17.0) 57 (13.2) 22 (13.3) 0.329
PAD 65 (7.4) 22 (7.8) 36 (8.4) 7 (4.2) 0.213
CVA 92 (10.5) 29 (10.3) 47 (10.9) 16 (9.6) 0.896
CHF 127 (14.4) 42 (14.9) 65 (15.1) 20 (12.0) 0.619
Arrhythmia 25 (2.8) 6 (2.1) 17 (3.9) 2 (1.2) 0.153
Diabetes 486 (55.3) 167 (59.2) 239 (55.5) 80 (48.2) 0.076
Connective tissue disease 85 (9.7) 25 (8.9) 43 (10.0) 17 (10.2) 0.853
Liver disease 81 (9.2) 17 (6.0) 39 (9.0) 25 (15.1) 0.006
CVD* 298 (33.9) 102 (36.2) 141 (32.7) 55 (33.1) 0.618
Cardiac disease{ 224 (25.5) 78 (27.7) 107 (24.8) 39 (23.5) 0.563
Modified CCI 5.162.6 5.162.5 5.162.6 4.962.6 0.665
SGA .1 278 (31.6) 84 (29.8) 144 (33.4) 50 (30.1) 0.535
KDQOL-SF score 60.1614.9 60.1614.8 60.5615.2 59.0614.3 0.696
Medications
RAS blockers 528 (60.1) 167 (59.2) 259 (60.1) 102 (61.4) 0.898
Diuretics 461 (52.4) 150 (53.2) 225 (52.2) 86 (51.8) 0.951
Beta blocker 477 (54.3) 170 (60.3) 229 (53.1) 78 (47.0) 0.019
CCB 549 (62.5) 183 (64.9) 263 (61.0) 103 (62.0) 0.576
Nitrate 34 (3.9) 10 (3.5) 13 (3.0) 11 (6.6) 0.116
Aspirin 214 (24.3) 81 (28.7) 98 (22.7) 35 (21.1) 0.106
Clopidogrel 73 (8.3) 31 (11.0) 30 (7.0) 12 (7.2) 0.139
Vitamin D 124 (14.1) 39 (13.8) 70 (16.2) 25 (15.1) 0.680
Ca based P-binders 472 (53.7) 164 (58.2) 224 (52.0) 84 (50.6) 0.182
ESA 282 (32.1) 83 (29.4) 148 (34.3) 51 (30.7) 0.358
Iron agent 319 (36.3) 95 (33.7) 160 (37.1) 64 (38.6) 0.516
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Table 2. Laboratory and echocardiographic findings of the patients.
Variables Total TSAT #20% TSAT 20–40% TSAT .40% P
Baseline laboratory data
WBC (/mL) 7239.162936.6 7637.263080.2 7055.162793.8 7039.662997.5 0.022
Hemoglobin (g/dL) 8.5561.43 8.5461.34 8.4761.41 8.4461.61 0.604
ALP (IU/L) 78.0 (59.0–109.0) 80.0 (60.0–109.0) 75.0 (57.0–105.0) 80.5 (59.0–115.3) 0.065
Ca (mg/dL) 8.2261.08 8.3260.96 8.2261.05 8.0661.30 0.048
P (mg/dL) 5.6161.38 5.5961.08 5.6061.36 5.8161.81 0.106
Ca x P product 45.4615.1 45.4613.7 45.3614.9 46.1617.7 0.239
Uric acid (mg/dL) 8.3662.13 8.2562.06 8.4062.07 8.5062.35 0.260
Glucose (mg/dL) 140.9637.4 141.6640.7 141.9639.5 137.0625.1 0.747
HbA1c (%) 6.1260.81 6.1260.90 6.1660.75 6.0260.81 0.570
Protein (g/dL) 6.0560.80 6.0860.76 6.0360.82 6.0660.82 0.702
Albumin (g/dL) 3.3260.59 3.2960.59 3.3360.57 3.3560.61 0.522
BUN (mg/dL) 82.7626.8 76.6622.7 82.3625.7 94.4633.4 ,0.001
Creatinine (mg/dL) 8.5263.52 7.9762.58 8.4263.32 9.7364.98 ,0.001
GFR-MDRD (mL/min/1.73m2) 7.1263.13 7.4063.42 7.1863.14 6.5162.54 0.080
GFR-EPI (mL/min/1.73m2) 7.2962.94 7.4762.76 7.3963.16 6.7262.60 0.111
Sodium (mEq/L) 137.264.9 137.064.6 137.365.0 137.465.0 0.763
Potassium(mEq/L) 4.6760.95 4.6160.95 4.6660.93 4.7961.01 0.115
Bicarbonate (mmol/L) 19.065.6 19.365.3 19.165.5 17.966.5 0.037
Intact-PTH (pg/mL) 203.9 (119.0–341.4) 198.7 (119.4–326.7) 210.0 (112.6–329.3) 209.9 (129.1–379.9) 0.413
Serum iron (mg/dL) 60.5632.0 29.868.9 61.2614.6 110.6633.9 ,0.001
TIBC (mg/dL) 217.7644.0 227.7651.9 216.5639.5 204.2637.2 ,0.001
TSAT (%) 28.4616.0 13.264.2 28.465.6 54.3613.0 ,0.001
Ferritin (ng/mL) 201.3 (103.5–363.4) 122.6 (64.3–274.1) 216.2 (121.6–369.8) 294.4 (190.3–479.9) ,0.001
Total cholesterol (mg/dL) 155.2646.3 153.9644.8 156.7646.9 151.5647.3 0.219
Triglyceride (mg/dL) 127.1654.8 127.3664.9 129.2651.0 116.7643.6 0.035
LDL-cholesterol (mg/dL) 89.3632.0 87.8629.3 92.6634.7 83.6628.6 0.044
HDL-cholesterol (mg/dL) 38.6612.5 38.4611.9 38.3612.2 39.9614.2 0.380
hs-CRP (mg/dL) 0.32 (0.08–1.46) 0.71 (0.15–2.09) 0.24 (0.06–0.99) 0.25 (0.07–1.20) ,0.001
Troponin-T (ng/mL) 0.056 (0.025–0.110) 0.057 (0.027–0.125) 0.059 (0.025–0.106) 0.046 (0.021–0.096) 0.409
NT-proBNP (pg/mL) 6505.4 (1576.7–25840.0) 11012.0 (1998.0–30000.0) 5969.5 (1364.0–21882.8) 4903.0 (1269.0–25151.5) 0.011
24-hr urine study
Urea (mg/dL) 220.0 (142.0–327.4) 190.1 (136.8–293.5) 238.8 (152.5–347.3) 206.7 (127.8–325.1) 0.018
Creatinine (mg/dL) 54.1 (38.0–86.6) 51.5 (36.4–76.0) 55.9 (38.4–91.3) 56.2 (36.6–84.1) 0.119
Protein (mg/day) 1180.5 (418.1–2794.5) 1153.0 (426.2–3150.5) 1305.6 (393.0–2951.7) 1053.0 (383.0–2604.0) 0.723
Volume (mL/day) 970.0 (600.0–1400.0) 990.0 (525.0–1445.0) 985.0 (600.0–1450.0) 880.0 (600.0–1300.0) 0.367
Echocardiographic parameters
LVPWT (cm) 1.2060.29 1.2160.29 1.1960.29 1.2060.27 0.737
IST (cm) 1.1560.22 1.1760.24 1.1460.22 1.1360.20 0.095
LVESD (cm) 3.5160.72 3.5860.75 3.4860.71 3.4360.69 0.062
LVEDD (cm) 5.1660.61 5.2060.61 5.1560.60 5.1260.63 0.329
LAD (cm) 4.2260.71 4.2760.71 4.2260.71 4.1360.69 0.131
LVMI (g/m2) 146.7643.4 151.7646.1 144.2642.1 144.5641.6 0.117
LVEF (%) 58.2611.3 57.3612.3 58.3611.1 59.3610.3 0.206
Abbreviations: WBC, white blood cell; ALP, alkaline phosphatase; Ca, calcium; P, phosphorus; HbA1C, hemoglobin A1C; BUN, blood urea nitrogen; GFR, glomerular
filtration rate; MDRD, Modification of Diet in Renal Disease; EPI, Chronic Kidney Disease Epidemiology Collaboration Equation; PTH, parathyroid hormone;TIBC, total iron
binding capacity; TSAT, transferrin saturation; LDL, low density lipoprotein; HDL, high density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; NT-proBNP, N-
terminal pro B-type natriuretic peptide; LVPWT, left ventricular posterior wall thickness; IST, inter-ventricularseptalthickness; LVESD, left ventricular end-systolic
dimension; LVEDD, left ventricular end-diastolic dimension; LAD, left atrial dimension; LVMI, left ventricular mass index; LVEF, left ventricular ejection fraction.
doi:10.1371/journal.pone.0087231.t002
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NT-proBNP (R=0.229, P= 0.134) and Ln cTnT concentrations
(R= 0.092, P= 0.406) (Table S4).
Discussion
TSAT is one of the available markers reflecting the adequacy of
iron for erythropoiesis and is closely correlated with Hb levels
[9,11]. Even though a number of studies have shown that anemia
is an independent risk factor for CV events and mortality in ESRD
patients, as well as in the general population [3,4,7,25], the impact
of TSAT on clinical outcome has never been explored in dialysis
patients. In the current study on incident dialysis patients with
anemia, we demonstrate for the first time that the lowest TSAT
group has significantly higher risk for CV composite outcome and
all-cause mortality, irrespective of Hb concentrations. In addition,
TSAT #20% was significantly associated with LVMI and hs-CRP
levels. These findings suggest that the adverse clinical outcomes in
patients with ‘low’ TSAT are partly attributed to LVH and
inflammation.
Iron deficiency is the most frequent cause of anemia in the
general population. In ESRD patients, a decrease in the
production of erythropoietin is the main factor contributing to
anemia, but iron deficiency anemia (IDA) is also prevalent [8].
Even though anemia has been demonstrated to be an independent
risk factor for renal function deterioration and CV morbidity/
mortality in patients with CKD [4,7,25], the results of some
previous studies on the impact of anemia correction on the clinical
outcome of CKD/ESRD patients have not been promising,
except for some improvement in quality of life [26–28]. Similarly,
anemia is common in patients with CHF, most of which are
attributed to ‘anemia of chronic disease’ or iron deficiency
[5,29,30]. Numerous previous studies demonstrated that anemia
was associated with impaired functional capacity and poor quality
of life in CHF patients, which were ameliorated by elimination of
the anemia [31,32]. However, a body of evidence indicating that
anemia correction has a beneficial effect on CV mortality in these
patients is lacking. Based on these findings, it is still debatable
whether adverse clinical outcomes in anemic patients are
attributed to anemia per se or other factors contributing to
anemia.
Iron is essential for normal cell physiology. In addition to its
critical role in erythropoiesis, iron is involved in the process of
oxygen transport and storage, oxidative metabolism including
ATP (adenosine triphosphate) production at the mitochondrial
electron transport chain in the form of cytochrome (a, b, c) and
iron-sulfur-containing dehydrogenases, and the synthesis and/or
degradation of RNA and DNA. Therefore, iron deficiency can
lead to not only anemia but also various cellular dysfunctions,
especially in high energy-requiring cells such as cardiomyocytes
and renal cells. In the clinical field, reduced oxidative capacity
caused by cytochrome dysfunction can manifest as fatigue,
impaired prolonged exercise, malnutrition, and cardiac dysfunc-
tion [12,33,34]. A previous study by Dong et al. [13] showed that
heart weight and size were significantly increased, and the left
Figure 1. Kaplan-Meier curves for CV composite outcome (A) and all-cause mortality (B) according to baseline TSAT concentrations.
The CV composites and all-cause mortality rates were significantly higher in patients with TSAT #20% compared to the other two groups.
Abbreviation: CV, cardiovascular; TSAT, transferrin saturation.
doi:10.1371/journal.pone.0087231.g001
Table 3. Comparisons of clinical outcomes according to the TSAT concentrations.
TSAT #20% 20% , TSAT #40% TSAT .40%
N (%)
Rates (per 100
patient-yr) N (%)
Rates (per 100
patient-yr) N (%)
Rates (per 100
patient-yr) P
CV mortality 12 (4.3%) 2.58 10 (2.3%) 1.44 7 (4.2%) 2.73 0.281
CV composite 51 (18.1%) 11.71 37 (8.6%) 5.55 19 (11.4%) 7.78 0.001
All-cause mortality 25 (8.9%) 5.38 16 (3.7%) 2.31 10 (6.0%) 3.90 0.016
*Composite: composite of death and hospitalization.
Abbreviations: TSAT, transferrin saturation; CV, cardiovascular.
doi:10.1371/journal.pone.0087231.t003
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ventricular dimension and chamber volume were significantly
enhanced, in rats fed an iron-deficient diet for 12 weeks.
Mitochondrial swelling and abnormal sarcomere structure were
also observed in ventricular tissues of the iron-deficient rats. These
findings inferred that iron deficiency per se might induce cardiac
dysfunction and morphological aberration. Moreover, another
recent study demonstrated that patients with advanced CHF
displayed significantly lower serum iron concentrations and TSAT
compared to healthy controls. This study also showed that
myocardial iron content and myocardial mRNA expression of
the type 1 transferrin receptor, a key molecule in cellular iron
transport, were significantly reduced in CHF versus non-CHF
samples, suggesting a linkage among the presence of iron depletion
in the failing heart, anemia, and adverse prognosis in CHF [35].
However, since hematocrit or Hb levels were significantly lower in
the iron-deficiency groups in those two studies, it was difficult to
conclude whether iron deficiency had a direct unfavorable impact
on the heart.
Recently, Jankowska et al. [15] found that iron deficiency,
defined as ferritin ,100 mg/L or ferritin 100-300 mg/L with
TSAT ,20%, rather than anemia, was an independent risk
factor for poor clinical outcome in 546 patients with stable
systolic CHF. Patients with iron deficiency had significantly lower
survival rates, either when death and heart transplantation or
death alone were considered events in both univariate and
multivariate Cox regression models, whereas anemia was a
significant predictor of adverse clinical outcome only in
univariate analysis. Based on these findings, they suggested that
iron deficiency had a direct deleterious effect on cardiomyocytes.
The results of the present study also showed that clinical
outcome was significantly worse in the lowest TSAT group,
despite comparable Hb concentrations, and that TSAT #20%
was a significant independent risk factor for CV composite
outcome and all-cause mortality. Taken together, we surmise that
the association between ‘low’ TSAT and adverse clinical
outcome in incident dialysis patients is a consequence of iron
deficiency rather than anemia in the heart, which may be partly
attributed to mitochondrial cytochrome dysfunction.
In a similar context, several clinical trials have shown the
beneficial effect of iron replacement therapy in CHF patients with
anemia. The first randomized trial was performed by Toblli et al.
[31] to evaluate the effect of intravenous iron therapy in anemic
patients with CHF and CKD, and demonstrated that iron
supplements substantially reduced NT-proBNP and inflammatory
Table 4. Hazard ratios and 95% confidence intervals for primary and secondary endpoints according to baseline TSAT
concentrations (Cox-proportional hazard regression analysis).
CV mortality CV composite All-cause mortality
HR 95% CI P HR 95% CI P HR 95% CI P
Unadjusted
TSAT #20% 1.798 0.777–4.161 0.171 1.918 1.256–2.929 0.003 2.117 1.130–3.965 0.019
20% , TSAT #40% 1 - - 1 - - 1 - -
TSAT .40% 1.881 0.716–4.941 0.200 1.420 0.817–2.469 0.214 1.714 0.778–3.777 0.182
Adjusted for demographics
TSAT #20% 1.651 0.710–3.841 0.245 1.729 1.123–2.661 0.013 2.278 1.190–4.363 0.013
20% , TSAT #40% 1 - - 1 - - 1 - -
TSAT .40% 1.785 0.675–4.724 0.243 1.499 0.859–2.616 0.154 1.749 0.760–4.026 0.189
Adjusted for demographics and medications
TSAT #20% 1.635 0.701–3.813 0.255 1.645 1.066–2.539 0.025 2.002 1.041–3.852 0.038
20% , TSAT #40% 1 - - 1 - - 1 - -
TSAT .40% 1.797 0.679–4.755 0.238 1.488 0.851–2.603 0.163 1.814 0.790–4.165 0.160
Adjusted for demographics, medications, and laboratory parameters
TSAT #20% 1.448 0.608–3.445 0.403 1.668 1.049–2.652 0.030 2.128 1.057–4.283 0.034
20% , TSAT #40% 1 - - 1 - - 1 - -
TSAT .40% 1.587 0.583–4.315 0.366 1.323 0.751–2.331 0.332 1.432 0.613–3.343 0.407
Adjusted for demographics, medications, laboratory parameters, and echocardiographic findings
TSAT #20% 1.383 0.555–3.448 0.486 1.616 1.008–2.607 0.046 2.193 1.081–4.450 0.030
20% , TSAT #40% 1 - - 1 - - 1 - -
TSAT .40% 1.687 0.580–4.908 0.337 1.212 0.673–2.185 0.522 1.292 0.533–3.129 0.571
*Composite: composite of death and hospitalization.
*CV mortality was sequentially adjusted for demographics (age, diabetes, underlying cardiovascular disease, and subjective global assessment score), medications
(aspirin), laboratory parameters (albumin, glucose, alkaline phosphatase, and log transformed high-sensitivity C-reactive protein), and echocardiographic findings (left
ventricular mass index and left ventricular ejection fraction).
*CV composite was sequentially adjusted for demographics (age, systolic blood pressure, diabetes, and underlying cardiovascular disease), medications (aspirin,
clopidogrel, vitamin D, and erythropoiesis-stimulating agents), laboratory parameters (calcium, glucose, potassium, log transformed ferritin, and log transformed high-
sensitivity C-reactive protein), and echocardiographic findings (left ventricular mass index and left ventricular ejection fraction).
*All-cause mortality was sequentially adjusted for demographics (body mass index, Charlson Comorbidity Index, and subjective global assessment score), medications
(aspirin, clopidogrel, and vitamin D), laboratory parameters (alkaline phosphatase, calcium, glucose, log transformed ferritin, and log transformed high-sensitivity C-
reactive protein), and echocardiographic findings (left ventricular mass index and left ventricular ejection fraction).
Abbreviations: TSAT, transferrin saturation; CV, cardiovascular; HR, hazard ratio; CI, confidence interval.
doi:10.1371/journal.pone.0087231.t004
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status in these patients, along with an improvement in LVEF, New
York Heart Association (NYHA) functional class, exercise
capacity, and quality of life. However, they found that Hb levels
were also significantly increased in the treatment group compared
to the placebo group. Recently, two prospective randomized
controlled trials showed that the correction of iron deficiency with
intravenous iron conferred symptomatic benefits in patients with
CHF [36,37]. Compared to the control group, patient global
assessment, exercise capacity, and NYHA functional class were
significantly improved in the iron-treated group regardless of the
presence of anemia, suggesting that iron deficiency per se was
detrimental to the heart. Considering the results of our study,
further studies on the use of intravenous iron in incident ESRD
patients with ‘low’ TSAT will be necessary to clarify whether iron
therapy can improve the clinical outcome of these patients, as in
CHF patients.
Meanwhile, an excess of iron can be toxic because it has the
ability to accept and donate electrons by exchanging between
ferrous and ferric forms. During this exchange, active free iron
undergoes ‘‘Fenton and Haber-Weiss reaction’’, causing oxidative
stress and organic biomolecule oxidation by releasing hydroxyl
radicals and other reactive oxygen species (ROS) [38,39].
Furthermore, in the vasculature, ROS produced at the endo-
thelium by excessive iron is known to promote the thrombotic
complications [33]. Even though ferritin concentration is usually
considered a marker of iron store and has been demonstrated to
be an independent predictor of clinical outcomes in not only the
general population but also specific patients groups, several
previous studies have found that TSAT, an indicator of a
predisposition for iron overload, is also a significant prognostic
factor in the general population. A cohort study using data from
the First Health and Nutrition Examination Survey I (NHANES
I) merged with the NHANES I Epidemiologic Follow Up Study
showed that all-cause mortality was significantly increased in
patients with a serum TSAT of more than 55% compared with
those with saturations below this cutoff [HR =1.60, 95%
confidence interval (CI) = 1.17–2.21], on a Cox proportional
hazard regression analysis [40]. In addition, Ellervik et al. [41]
examined mortality according to baseline TSAT in two Danish
population-based follow-up studies and demonstrated that the
cumulative survival was significantly reduced in individuals with
TSAT $50% vs. ,50% (P,0.0001). In that study, there was a
Table 5. Odds ratios and 95% confidence intervals for echocardiographic parameters according to baseline TSAT concentrations
(Logistic regression analysis).
Unadjusted Adjusted
OR 95% CI P OR 95% CI P
Left ventricular ejection fraction ,60%
TSAT #20% 1.435 1.068–1.926 0.016 1.313 0.910–1.895 0.146
20% , TSAT #40% 1 - - 1 - -
TSAT .40% 0.969 0.689–1.363 0.857 0.715 0.466–1.096 0.124
Left ventricular hypertrophy
TSAT #20% 1.482 1.065–2.062 0.020 1.455 1.003–2.110 0.048
20% , TSAT #40% 1 - - 1 - -
TSAT .40% 0.838 0.574–1.224 0.361 0.931 0.604–1.435 0.747
Left ventricular end-diastolic dimension $55 mm
TSAT #20% 1.363 0.981–1.892 0.065 1.258 0.849–1.862 0.252
20% , TSAT #40% 1 - - 1 - -
TSAT .40% 0.941 0.624–1.418 0.770 0.765 0.474–1.235 0.274
Left ventricular end-systolic dimension $35 mm
TSAT #20% 1.346 0.995–1.821 0.054 1.341 0.935–1.924 0.111
20% , TSAT #40% 1 - - 1 - -
TSAT .40% 0.888 0.617–1.277 0.522 0.687 0.449–1.052 0.084
Left atrial dimension $40 mm
TSAT #20% 1.456 1.051–2.015 0.024 1.145 0.777–1.689 0.494
20% , TSAT #40% 1 - - 1 - -
TSAT .40% 0.835 0.578–1.205 0.335 0.725 0.468–1.124 0.150
*Left ventricular ejection fraction was adjusted for sex, body mass index, heart rates, underlying diabetes and cardiovascular disease, hemoglobin, serum glucose,
albumin, and creatinine levels, log transformed high-sensitivity C-reactive protein, and usage of diuretics, beta blockers, and vitamin D.
*Left ventricular hypertrophy was adjusted for sex, diastolic blood pressure, underlying cardiac disease, subjective global assessment score, hemoglobin, serum calcium,
and albumin concentrations, and usage of renin-angiotensin system blockers and beta blockers.
*Left ventricular end-diastolic dimension was adjusted for sex, body mass index, underlying diabetes and cardiac disease, smoking status, hemoglobin, serum
phosphorus and albumin levels, log transformed high-sensitivity C-reactive protein, and usage of renin-angiotensin system blockers and beta blockers.
*Left ventricular end-systolic dimension was adjusted for sex, diastolic blood pressure, underlying cardiovascular disease, smoking status, hemoglobin, serum
phosphorus, albumin, and creatinine concentrations, log transformed high-sensitivity C-reactive protein, and usage of renin-angiotensin system blockers and beta
blockers.
*Left atrial dimension was adjusted for age, sex, pulse pressure, underlying diabetes and cardiac disease, smoking status, hemoglobin, serum albumin levels, log
transformed high-sensitivity C-reactive protein, and usage of diuretics, beta blockers, calcium channel blockers, and aspirin.
Abbreviations: TSAT, transferrin saturation; OR, odds ratio; CI, confidence interval.
doi:10.1371/journal.pone.0087231.t005
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stepwise increase in all-cause mortality, with the first significant
increased risk conferred by TSAT $40%. Based on these
findings, we tried to elucidate the impact of iron deficiency as
well as a proxy of iron overload, and thus categorized patients
into 3 groups based on TSAT; #20% (low), 20–40% (normal),
and .40% (high). Even though HRs for clinical outcomes; CV
mortality, CV composite, and all-cause mortality; were slightly
increased in patients with TSAT .40%, there were no statistical
significances. In another analysis conducted after dichotomizing
the study subjects into just ‘low’ and ‘normal to high’ TSAT
groups, patients with TSAT #20% showed significantly higher
rates of CV composite outcome and all-cause mortality, and the
HRs for each outcome were 1.53 and 2.04, respectively, which
were comparable with those of the original analysis. These data
indirectly implicate the lack of statistical difference between the
reference group and subjects with TSAT .40%, and further
clarify our finding of low TSAT (#20%) as a risk factor for
adverse clinical outcomes.
LVH is a well-known powerful independent predictor of CV
morbidity and mortality in patients with ESRD. Furthermore, a
change in LVH has been identified as a strong prognostic factor
in these patients. A previous prospective study on prevalent HD
patients revealed that the rates of LVMI increase were
significantly higher in patients with incident CV events than in
those without such events and that cardiovascular event-free
survival in patients with changes in LVMI below the 25th
percentile was significantly higher than in those with changes
above the 75th percentile [42]. Similarly, in a cohort study of
153 incident ESRD patients receiving HD, a reduction in LV
mass during a mean follow-up duration of 54 months resulted in
significant decreases in all-cause and CV mortality. In that study,
LV mass reduction was also independently associated with
improved patient survival, even after adjustment for confounding
variables [43]. On the other hand, uremia-related nontraditional
risk factors, including inflammation and oxidative stress, were
implicated in the pathogenesis of CV disease in dialysis patients
[44]. Since accumulating evidence indicates that inflammation is
an integral part of the development and progression of
atherosclerosis, it has been proposed that hs-CRP concentrations
are closely linked to the presence of CV disease. In addition,
numerous previous studies have found that serum hs-CRP levels
are predictive of CV mortality, as well as future CV events, in
not only the general population but also ESRD patients [45,46].
In this study, LVMI and serum hs-CRP concentrations were
higher in the lowest TSAT group compared to the other two
groups. Moreover, TSAT #20% was found to be a significant
determinant of LVMI and Ln hs-CRP concentrations in
multivariate linear regression analysis. Taken together, the
impact of ‘low’ TSAT on clinical outcome in our patients seems
to be partly mediated by LVH and inflammation.
Several shortcomings of the current study should be discussed.
First, since the study subjects were all Korean incident ESRD
patients, the association of TSAT with mortality and composite
outcome may not be generalizable to other populations. Second,
because only the baseline laboratory and echocardiographic
measurements were used for the analysis, it was difficult to
demonstrate the impact of the changes of TSAT on patients’
clinical outcomes. Third, even though CV disease was the
leading cause of death in our subjects, CV mortality was
comparable among the three groups in spite of a significant
difference in all-cause mortality, which may be attributed to ‘low’
CV mortality rates in the current study compared to those in
previous studies on Western ESRD patients. We propose that the
difference is mainly attributed to disparate ethnicities as the
mortality rates of our patients were not significantly different
from those of Japanese dialysis patients [47]. Fourth, we stratified
the patients based on TSAT only, without considering ferritin
levels, indicating that patients with TSAT #20% may not be
purely iron deficient. Since ferritin is an acute-phase reactant,
high ferritin concentrations with low TSAT may imply a
condition of iron sequestration, which is a characteristic of
‘anemia of chronic disease’. In the present study, in fact, there
was a significant correlation between serum ferritin levels and Ln
hs-CRP concentrations (r = 0.368, P,0.001), whereas Hb levels
did not correlate with serum ferritin concentrations (r = 0.002,
P= 0.954). Fifth, TSAT is also known to be influenced by
nutritional status. TIBC may be decreased due to reduced
transferrin synthesis in the setting of malnutrition and chronic
disease, resulting in high TSAT, disproportionate to the iron
content [11]. However, serum albumin levels were not signifi-
Table 6. Odds ratios and 95% confidence intervals for serum
inflammatory and cardiac biomarkers according to baseline
TSAT concentrations (Logistic regression analysis).
Unadjusted Adjusted
OR 95% CI P OR 95% CI P
hs-CRP $3 mg/dL
TSAT #20% 1.772 1.162–
2.702
0.008 2.087 1.292–3.372 0.003
20% , TSAT
#40%
1 - - 1 - -
TSAT .40% 0.980 0.558–
1.722
0.945 0.817 0.443–1.506 0.517
NT-proBNP $10000
pg/mL
TSAT #20% 1.630 1.124–
2.363
0.010 2.039 1.181–3.521 0.011
20% , TSAT
#40%
1 - - 1 - -
TSAT .40% 0.640 0.400–
1.023
0.062 0.328 0.171–0.629 0.001
Troponin-T $0.1 ng/mL
TSAT #20% 1.498 1.004–
2.235
0.048 2.019 1.104–3.691 0.023
20% , TSAT
#40%
1 - - 1 - -
TSAT .40% 0.876 0.518–
1.484
0.623 0.989 0.484–2.024 0.976
*hs-CRP was adjusted for Charlson Comorbidity Index, subjective global
assessment score, smoking status, hemoglobin, serum calcium, glucose,
albumin, and sodium concentrations, and log transformed ferritin.
*NT-proBNP was adjusted for diastolic blood pressure, underlying diabetes and
cardiac disease, hemoglobin, serum glucose, albumin, creatinine, and sodium
levels, log transformed high-sensitivity C-reactive protein, log transformed
ferritin, log transformed troponin-T, and usage of renin-angiotensin system
blockers, diuretics, and beta blockers.
*Troponin-T was adjusted for sex, systolic blood pressure, underlying diabetes
and cardiac disease, subjective global assessment score, hemoglobin, serum
calcium, glucose, and albumin concentrations, log transformed high-sensitivity
C-reactive protein, log transformed ferritin, log transformed 24-hr urine volume,
left atrial dimension, left ventricular mass index, left ventricular ejection fraction,
and usage of diuretics and nitrate.
Abbreviations: hs-CRP, high-sensitivity C-reactive protein; NT-proBNP, N-terminal
pro B-type natriuretic peptide; TSAT, transferrin saturation; OR, odds ratio; CI,
confidence interval.
doi:10.1371/journal.pone.0087231.t006
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cantly different among the three groups, suggesting that TSAT
was not largely affected by nutritional status in our patients.
Sixth, data for transfusion were not available. So, we excluded
patients who had a history of acute/recent bleeding in the
analysis. Lastly, about one-third of patients were already taking
iron or ESA agents at the time of inclusion. Nevertheless, the
proportions of patients taking those medications were not
significantly different among the three groups, and multivariate
analysis was conducted after adjusting for these factors. Despite
these limitations, to our knowledge, the current study is the first
study to investigate the impact of TSAT at the time of dialysis
initiation on clinical outcome in a large and single-ethnicity
incident dialysis patient cohort. Further studies will be needed to
elucidate whether serial monitoring, rather than a single
measurement of TSAT, is helpful in identifying ESRD patients
at a high risk of all-cause and CV morbidity and mortality and
whether iron supplements are beneficial to clinical outcome in
‘low’ TSAT patients.
In conclusion, ‘low’ TSAT was a significant independent risk
factor for CV composite outcome and all-cause mortality in
incident dialysis patients with anemia. Furthermore, TSAT #20%
was significantly associated with LVMI and hs-CRP concentra-
tions. These findings suggest that the adverse clinical outcomes in
patients with ‘low’ TSAT are partly attributed to LVH and
inflammation.
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